KMD Bioscience Co., Ltd.
400-621-6806
Service Line：+1-315-239-3085
Address：FL-4, Building A5, International Enterprise Community, Tianjin, China
Email：info@kmdbioscience.com
| Catalog Number | YR1315 |
|---|---|
| Product Name | Anti-Human FZD Recombinant Antibody |
| Molecular Name | Vantictumab |
| Alias | Anti-FZD Recombinant Antibody, Research Grade Vantictumab |
| CAS Number | 1345009-45-1 |
| Target | FZD[Homo sapiens] |
| Isotype | IgG2 Lambda |
| Clonity | Monoclonal |
| Source | CHO Cells |
| Size | 1mg, 5mg |
| Concentration | 1mg/ml |
| Purity | >95% as determined by SDS-PAGE |
| Applications | Inhib, FCM |
| Buffer | PBS, pH7.5 |
| Background | Vantictumab /vænˈtɪktʊmæb/ is a human IgG2 monoclonal antibody designed for the treatment of cancer. This drug was developed by OncoMed Pharmaceuticals Inc. in partnership with Bayer. OncoMed was awarded a patent in 2016, which is set to expire in 2029.[3] In April 2017, Bayer terminated its option to license vantictumab. |
| Storage | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
| Note | This product is for research use only. |
FL-4, Building A5, International Enterprise Community, Tianjin, China
Email：info@kmdbioscience.com
Hot Line： +1-315-239-3085
Technical Support：sales@kmdbiosci.com
